Search

Jonathan A Terrett

from Sunnyvale, CA
Get Report
Also known as:
J Terrett
Related to:
Tracey Terrett, 56
Connected to:
David Terrett, 36Laura L Terrett, 72Michael S Terretta, 56Richard D Terrett, 88Yoko A Terretta, 51Kevin M Terrey, 52Steven J Terrezza, 36James M Terri, 51Joann A Terri, 79John Terri, 48

Jonathan Terrett Phones & Addresses

  • Sunnyvale, CA
  • Cupertino, CA
  • Los Altos, CA
  • 1106 S Mary Ave, Sunnyvale, CA 94087

Publications

Us Patents

Human Monoclonal Antibodies To Protein Tyrosine Kinase 7 (Ptk7) And Methods For Using Anti-Ptk7 Antibodies

View page
US Patent:
8222375, Jul 17, 2012
Filed:
Dec 8, 2006
Appl. No.:
12/095986
Inventors:
Jonathan Alexander Terrett - Sunnyvale CA, US
Li-Sheng Lu - Mountain View CA, US
Chin Pan - Los Altos CA, US
Assignee:
MEDAREX, Inc. - Princeton NJ
International Classification:
C07K 16/40
C07K 16/00
A61K 39/395
US Classification:
53038826, 53038815, 5303881, 5303871, 4241461, 4241411, 4241301
Abstract:
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.

Human Antibodies That Bind Mesothelin, And Uses Thereof

View page
US Patent:
8268970, Sep 18, 2012
Filed:
Sep 29, 2008
Appl. No.:
12/681215
Inventors:
Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07K 16/00
C12P 21/08
US Classification:
5303871, 5303873, 53038815
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

Human Antibodies That Bind Mesothelin, And Uses Thereof

View page
US Patent:
8383779, Feb 26, 2013
Filed:
Aug 16, 2012
Appl. No.:
13/587572
Inventors:
Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07K 16/00
C12P 21/08
US Classification:
5303871, 5303873, 53038815
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

Human Antibodies That Bind Mesothelin, And Uses Thereof

View page
US Patent:
8399623, Mar 19, 2013
Filed:
Aug 16, 2012
Appl. No.:
13/587500
Inventors:
Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07K 16/00
C12P 21/08
US Classification:
5303871, 5303873, 53038815
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

Fully Human Antibodies Specific To Cadm1

View page
US Patent:
8420084, Apr 16, 2013
Filed:
Mar 5, 2010
Appl. No.:
13/254752
Inventors:
Jonathan Alexander Terrett - Sunnyvale CA, US
Heidi Leblanc - Mountain View CA, US
Haichun Huang - Fremont CA, US
Erika Meaddough - Gilroy CA, US
Chin Pan - Los Altos CA, US
Bingliang Chen - Alameda CA, US
Assignee:
Medarex, Inc. - Princeton NJ
Oxford BioTherapeutics Ltd - Abingdon
International Classification:
A61K 39/395
C07K 16/00
C07K 16/46
US Classification:
4241301, 4241331, 4241381, 5303871, 5303873, 53038825, 5303917
Abstract:
The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.

Matriptase Protein And Uses Thereof

View page
US Patent:
8420091, Apr 16, 2013
Filed:
Feb 7, 2010
Appl. No.:
12/701566
Inventors:
Christian Rohlff - Abingdon, GB
Jonathan Alexander Terrett - San Jose CA, US
Assignee:
Oxford BioTherapeutics Ltd. - Abingdon
Medarex, Inc. - Princeton NJ
International Classification:
A61K 39/395
US Classification:
4241411
Abstract:
The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.

Human Antibodies That Bind Mesothelin, And Uses Thereof

View page
US Patent:
8425904, Apr 23, 2013
Filed:
Aug 16, 2012
Appl. No.:
13/587644
Inventors:
Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 39/395
A61K 39/00
US Classification:
4241301, 4241781, 4241421, 4241551
Abstract:
The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

Antibody Drug Conjugate Treatment Of Colorectal Cancer

View page
US Patent:
8535677, Sep 17, 2013
Filed:
Dec 1, 2010
Appl. No.:
12/958373
Inventors:
Christian Rohlff - Abingdon, GB
Jonathan Alexander Terrett - San Jose CA, US
Assignee:
Oxford Biotherapeutics, Ltd. - Oxon
International Classification:
A61K 39/00
US Classification:
4241781
Abstract:
The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.
Control profile
Jonathan A Terrett from Sunnyvale, CA Get Report